Nuvalent (NUVL) Competitors

Insmed (NASDAQ:INSM) and Nuvalent (NASDAQ:NUVL) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, media sentiment and dividends.

Which has more volatility and risk, INSM or NUVL?

Insmed has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500. Comparatively, Nuvalent has a beta of 1.31, indicating that its stock price is 31% more volatile than the S&P 500.

Which has stronger earnings & valuation, INSM or NUVL?

Nuvalent has lower revenue, but higher earnings than Insmed. Nuvalent is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$381.03M	51.87	-$913.77M	-$5.95	-17.51
Nuvalent	N/A	N/A	-$260.76M	-$4.39	-19.52

Do analysts rate INSM or NUVL?

Insmed currently has a consensus target price of $108.47, indicating a potential upside of 4.12%. Nuvalent has a consensus target price of $119.60, indicating a potential upside of 39.57%. Given Nuvalent's stronger consensus rating and higher probable upside, analysts clearly believe Nuvalent is more favorable than Insmed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	0 Sell rating(s)	0 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	3.00
Nuvalent	0 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.17

Do institutionals & insiders believe in INSM or NUVL?

97.3% of Nuvalent shares are owned by institutional investors. 3.0% of Insmed shares are owned by insiders. Comparatively, 10.2% of Nuvalent shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Is INSM or NUVL more profitable?

Nuvalent has a net margin of 0.00% compared to Insmed's net margin of -265.93%. Nuvalent's return on equity of -31.35% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-265.93%	-446.98%	-52.70%
Nuvalent	N/A	-31.35%	-29.27%

Does the media prefer INSM or NUVL?

In the previous week, Insmed had 12 more articles in the media than Nuvalent. MarketBeat recorded 19 mentions for Insmed and 7 mentions for Nuvalent. Insmed's average media sentiment score of 0.85 beat Nuvalent's score of 0.59 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	12 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nuvalent	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Nuvalent beats Insmed on 11 of the 16 factors compared between the two stocks.